The Delhi High Court has issued a restraining order against Dr. Reddy’s Laboratories, preventing the company from using the ‘SUN’ mark on their sunscreen product labels. This decision comes after a lawsuit was filed by Sun Pharmaceutical Industries, which claimed that Dr. Reddy’s was infringing on their trademark rights. <\/p>\n
Sun Pharmaceutical Industries had been using the ‘SUN’ mark for their various pharmaceutical products, including sunscreens, and had registered the trademark in 2002. The company argued that Dr. Reddy’s use of the ‘SUN’ mark on their sunscreen labels would cause confusion among consumers and dilute the distinctiveness of their trademark.<\/p>\n
The Delhi High Court agreed with Sun Pharmaceutical Industries, stating that Dr. Reddy’s use of the ‘SUN’ mark was likely to cause confusion among consumers. The court also noted that Dr. Reddy’s had not provided any evidence to show that they had been using the ‘SUN’ mark prior to Sun Pharmaceutical Industries’ registration of the trademark.<\/p>\n
As a result of the court’s decision, Dr. Reddy’s will be required to remove the ‘SUN’ mark from their sunscreen product labels and packaging. The company will also be prohibited from using any other marks that are similar to the ‘SUN’ mark, in order to avoid causing confusion among consumers.<\/p>\n
This decision highlights the importance of protecting intellectual property rights, particularly in the pharmaceutical industry where consumer safety and trust are paramount. It also demonstrates the proactive approach taken by the Delhi High Court in enforcing trademark rights and preventing infringement.<\/p>\n
The court’s decision is a significant victory for Sun Pharmaceutical Industries, which had invested significant time and resources into building their brand and protecting their trademark. The company can now continue to use the ‘SUN’ mark without fear of confusion or dilution, and can focus on providing high-quality products to consumers.<\/p>\n
In contrast, Dr. Reddy’s will need to rebrand their sunscreen products and find alternative names or marks that do not infringe on Sun Pharmaceutical Industries’ trademark rights. This may require significant investments in marketing and advertising, as well as changes to their product packaging and labeling.<\/p>\n
Overall, the Delhi High Court’s decision in this case emphasizes the importance of respecting intellectual property rights and the need for companies to conduct thorough trademark searches before launching new products or using new marks. It also highlights the role of the courts in protecting trademark rights and preventing infringement, and the need for companies to be vigilant in defending their intellectual property.<\/p>\n","protected":false},"excerpt":{"rendered":"
The Delhi High Court has issued a restraining order against Dr. Reddy’s Laboratories, preventing the company from using the ‘SUN’ mark on their sunscreen product labels. This decision comes after a lawsuit was filed by Sun Pharmaceutical Industries, which claimed that Dr. Reddy’s was infringing on their trademark rights. Sun Pharmaceutical Industries had been using […]<\/p>\n","protected":false},"author":1,"featured_media":88041,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[15],"tags":[],"class_list":["post-89721","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dr-reddys"],"jetpack_featured_media_url":"https:\/\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89748,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/04\/delhi-high-court-bars-dr-reddys-from-producing-venusia-sunscreens-bearing-the-sun-logo\/","url_meta":{"origin":89721,"position":0},"title":"Delhi High Court bars Dr Reddy’s from producing VENUSIA sunscreens bearing the SUN logo.","author":"Team Small News","date":"January 4, 2026","format":false,"excerpt":"The Delhi High Court has issued an interim order restraining Dr. Reddy's Laboratories from manufacturing and selling its VENUSIA sunscreens with a label that includes the word \"SUN\". The court's decision comes in response to a lawsuit filed by Glenmark Pharmaceuticals, which claims that Dr. Reddy's is infringing on its\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89743,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/03\/bombay-high-court-denies-sun-pharmas-request-for-temporary-restraining-order-against-competitor-esiraft-allowing-it-to-continue-challenging-raciraft\/","url_meta":{"origin":89721,"position":1},"title":"Bombay High Court Denies Sun Pharma’s Request for Temporary Restraining Order Against Competitor EsiRaft, Allowing it to Continue Challenging RACIRAFT","author":"Team Small News","date":"January 3, 2026","format":false,"excerpt":"The Bombay High Court has refused to grant an interim injunction to Sun Pharmaceutical Industries Limited, allowing Meghmani Lifesciences Limited to continue using the trademark \"EsiRaft\" for its pharmaceutical product. The court found that the mark is not deceptively similar to Sun Pharma's \"RACIRAFT\" and that there is no likelihood\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":89757,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/06\/sun-pharmaceutical-industries-suffers-loss-in-trademark-dispute-as-bombay-high-court-rules-esiraft-and-raciraft-do-not-bear-deceptive-similarities\/","url_meta":{"origin":89721,"position":2},"title":"Sun Pharmaceutical Industries suffers loss in trademark dispute as Bombay High Court rules EsiRaft and Raciraft do not bear deceptive similarities.","author":"Team Small News","date":"January 6, 2026","format":false,"excerpt":"The Bombay High Court has ruled in favor of Eris Lifesciences, dismissing Sun Pharmaceutical's claim that Eris's medication \"EsiRaft\" infringed on Sun Pharma's trademark for their medication \"Raciraft\". The court found that the names \"EsiRaft\" and \"Raciraft\" are not deceptively similar, and therefore, Eris Lifesciences did not infringe on Sun\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":89836,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/22\/dr-reddys-relies-on-biosimilars-and-weight-loss-medication-launches-to-compensate-for-declining-us-dominance-of-revlimid\/","url_meta":{"origin":89721,"position":3},"title":"Dr Reddy’s relies on biosimilars and weight-loss medication launches to compensate for declining US dominance of Revlimid.","author":"Team Small News","date":"January 22, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories, a leading Indian pharmaceutical company, is shifting its focus towards biosimilars and a new weight-loss drug to drive growth as its exclusivity for the generic version of Revlimid in the US market is set to expire. Revlimid, a blood cancer treatment, has been a significant contributor to\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89794,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/13\/dr-reddys-laboratories-has-been-issued-a-pre-approval-inspection-letter-from-the-usfda-for-its-biologics-facility-located-in-hyderabad\/","url_meta":{"origin":89721,"position":4},"title":"Dr. Reddy’s Laboratories has been issued a pre-approval inspection letter from the USFDA for its biologics facility located in Hyderabad.","author":"Team Small News","date":"January 13, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories has received a Pre-Approval Inspection (PAI) letter from the US Food and Drug Administration (USFDA) for its biologics facility located in Hyderabad, India. This letter indicates that the USFDA has completed its inspection of the facility and has found it to be compliant with the required standards.\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89727,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/31\/gurupyar-reddy-production-complex-injections-head-at-dr-reddys-laboratories\/","url_meta":{"origin":89721,"position":5},"title":"Gurupyar Reddy, Production Complex Injections Head at Dr Reddy’s Laboratories","author":"Team Small News","date":"December 31, 2025","format":false,"excerpt":"The Vizag Pharma Summit 2025 is scheduled to take place on December 17th, 2025, at the Fairfield by Marriott in Vizag. The event will feature a speaker, Mr. Gurupyar Reddy, who is the Head of Production Complex Injections at Dr. Reddy's Laboratories. Mr. Reddy will be discussing the topic of\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89721","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89721"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89721\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media\/88041"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89721"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89721"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89721"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}